284 related articles for article (PubMed ID: 22302269)
1. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal sarcomatosis.
Salti GI; Ailabouni L; Undevia S
Ann Surg Oncol; 2012 May; 19(5):1410-5. PubMed ID: 22302269
[TBL] [Abstract][Full Text] [Related]
2. Peritoneal sarcomatosis: is there a subset of patients who may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy?
Baratti D; Pennacchioli E; Kusamura S; Fiore M; Balestra MR; Colombo C; Mingrone E; Gronchi A; Deraco M
Ann Surg Oncol; 2010 Dec; 17(12):3220-8. PubMed ID: 20585874
[TBL] [Abstract][Full Text] [Related]
3. Aggressive locoregional management of recurrent peritoneal sarcomatosis.
Baumgartner JM; Ahrendt SA; Pingpank JF; Holtzman MP; Ramalingam L; Jones HL; Zureikat AH; Zeh HJ; Bartlett DL; Choudry HA
J Surg Oncol; 2013 Mar; 107(4):329-34. PubMed ID: 23386388
[TBL] [Abstract][Full Text] [Related]
4. The role of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade appendiceal carcinoma and extensive peritoneal carcinomatosis.
El Halabi H; Gushchin V; Francis J; Athas N; Macdonald R; Nieroda C; Studeman K; Sardi A
Ann Surg Oncol; 2012 Jan; 19(1):110-4. PubMed ID: 21701929
[TBL] [Abstract][Full Text] [Related]
5. Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Nonaka D; Oliva GD; Laterza B; Deraco M
Ann Surg Oncol; 2007 Oct; 14(10):2790-7. PubMed ID: 17661150
[TBL] [Abstract][Full Text] [Related]
6. Peritonectomy and hyperthermic chemotherapy in patients with advanced or recurrent ephitelial ovarian cancer: a single center cohort study.
Massari R; Barone M; Basilico R; Carella C; Colasante A; De Tursi M; Filippone A; Guetti L; Mani A
Minerva Chir; 2014 Feb; 69(1):17-26. PubMed ID: 24675243
[TBL] [Abstract][Full Text] [Related]
7. Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis: clinical outcome and prognostic factors in 60 consecutive patients.
Rossi CR; Deraco M; De Simone M; Mocellin S; Pilati P; Foletto M; Cavaliere F; Kusamura S; Gronchi A; Lise M
Cancer; 2004 May; 100(9):1943-50. PubMed ID: 15112276
[TBL] [Abstract][Full Text] [Related]
8. Treatment of peritoneal carcinomatosis from colonic cancer by cytoreduction, peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC). Experience of ten years.
Vaira M; Cioppa T; D'Amico S; de Marco G; D'Alessandro M; Fiorentini G; De Simone M
In Vivo; 2010; 24(1):79-84. PubMed ID: 20133981
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience.
Chua TC; Yan TD; Morris DL
J Surg Oncol; 2009 Feb; 99(2):109-13. PubMed ID: 19016259
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of complete cytoreductive surgery and two intraperitoneal chemotherapy techniques in Pseudomyxoma peritonei.
Sørensen O; Flatmark K; Reed W; Wiig JN; Dueland S; Giercksky KE; Larsen SG
Eur J Surg Oncol; 2012 Oct; 38(10):969-76. PubMed ID: 22763244
[TBL] [Abstract][Full Text] [Related]
11. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Cabras AD; Bertulli R; Hutanu I; Deraco M
Eur J Cancer; 2013 Oct; 49(15):3140-8. PubMed ID: 23831335
[TBL] [Abstract][Full Text] [Related]
12. The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study.
Hompes D; D'Hoore A; Van Cutsem E; Fieuws S; Ceelen W; Peeters M; Van der Speeten K; Bertrand C; Legendre H; Kerger J
Ann Surg Oncol; 2012 Jul; 19(7):2186-94. PubMed ID: 22395983
[TBL] [Abstract][Full Text] [Related]
13. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.
Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS
World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149
[TBL] [Abstract][Full Text] [Related]
14. Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Baratti D; Vaira M; Kusamura S; D'Amico S; Balestra MR; Cioppa T; Mingrone E; De Simone M; Deraco M
Eur J Surg Oncol; 2010 Nov; 36(11):1047-53. PubMed ID: 20832234
[TBL] [Abstract][Full Text] [Related]
15. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion.
Deraco M; Nonaka D; Baratti D; Casali P; Rosai J; Younan R; Salvatore A; Cabras Ad AD; Kusamura S
Ann Surg Oncol; 2006 Feb; 13(2):229-37. PubMed ID: 16444562
[TBL] [Abstract][Full Text] [Related]
16. Utility of Chemoresponse Assay in Patients Undergoing Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy.
Bhagwandin S; Naffouje S; Salti G
Ann Surg Oncol; 2015 Aug; 22(8):2573-7. PubMed ID: 25572680
[TBL] [Abstract][Full Text] [Related]
17. Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer.
Ceelen WP; Van Nieuwenhove Y; Van Belle S; Denys H; Pattyn P
Ann Surg Oncol; 2012 Jul; 19(7):2352-9. PubMed ID: 20039210
[TBL] [Abstract][Full Text] [Related]
18. Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Cabras AD; Dileo P; Laterza B; Deraco M
Ann Surg Oncol; 2009 Feb; 16(2):463-72. PubMed ID: 19082859
[TBL] [Abstract][Full Text] [Related]
19. Toxicity and outcomes associated with surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with sarcomatosis.
Lim SJ; Cormier JN; Feig BW; Mansfield PF; Benjamin RS; Griffin JR; Chase JL; Pisters PW; Pollock RE; Hunt KK
Ann Surg Oncol; 2007 Aug; 14(8):2309-18. PubMed ID: 17541691
[TBL] [Abstract][Full Text] [Related]
20. Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience.
Vaira M; Cioppa T; DE Marco G; Bing C; D'Amico S; D'Alessandro M; Fiorentini G; DE Simone M
In Vivo; 2009; 23(4):639-44. PubMed ID: 19567401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
